Credit Suisse’s Starling Oncology STLN Stock Holding History

Credit Suisse’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1	Closed	-$2	–	3703
2022 Q4	$2	Sell	1 -192	-99%	-$539	﹤0.01%	3902
2022 Q3	$1K	Sell	193 -53	-22%	-$312	﹤0.01%	3935
2022 Q2	$1K	Buy	+246	New	+$1.79K	﹤0.01%	3842

Other funds holding STLN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Credit Suisse's STLN Position: Q1 2023 in Review

Credit Suisse sold out of Starling Oncology (STLN) in Q1 2023, closing a stake of 1 share — an estimated $2 sold.

Credit Suisse first reported a position in STLN in Q2 2022 and held it in 3 quarters. The position peaked at $1K in Q3 2022. 39 funds tracked by Wall St. Rank hold STLN as of Q1 2023.

Credit Suisse reported no remaining Starling Oncology position as of Q1 2023 after selling out during the quarter.
Credit Suisse sold 1 Starling Oncology share in Q1 2023, an estimated $2.
Credit Suisse first reported a position in Starling Oncology in Q2 2022 and held it in 3 quarters.
Credit Suisse's Starling Oncology position peaked at $1K in Q3 2022.
39 funds tracked by Wall St. Rank held Starling Oncology as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.